Unit 014 · Screen review
Commission review
Authorize backfills and match reversals to evidence.
Financial review examples only. Placeholder rates cannot create payable commissions.
Backfills to authorize
| Affiliate | Rate decision reference | Retro scope | Amount | Action |
|---|---|---|---|---|
| Test Agency LLC | decision:TestRateOctV2 | Sep 1, 2026 to Sep 30, 2026 · 20 paid months | $240.00 |
Reversals matched
| Commission | Refund evidence | Paid month | Reversal | Status |
|---|---|---|---|---|
| TestCommission014 | source:TestRefundReceipt44 | Sep 2026 | -$12.00 | Matched |
Evidence pending
| Affiliate | Missing evidence | Evidence source | Hold | Action |
|---|---|---|---|---|
| Test North Agency LLC | Paid month confirmation | BaxRx observation · source:TestObservation77 | Commission not eligible |
Suspicious patterns from unit 016
| Affiliate | Signal | Evidence source | Imposed hold | Action |
|---|---|---|---|---|
| Test South Agency LLC | Refund spike: 12 of 100 paid months | risk:TestRefundSpike16 | Payout and related commissions | Review risk |
Fictitious data. Interactions change this preview only. Nothing is live. Approval references and drug results are illustrative.